COX-2 and colorectal cancer

Current Pharmaceutical Design

Volumn 9, Issue 27, 2003, Pages 2229-2251

  Ferrández, Angel ^a   Prescott, S ^a   Burt, R W ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Colorectal cancer; Cyclooxygenase; NSAIDs; Prostaglandins

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; MECLOFENAMIC ACID; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; TILMACOXIB;

APOPTOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CANCER RISK; CARCINOGENESIS; CATALYSIS; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HUMAN; METABOLITE; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0141587879     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454036     Document Type: Review

References (237)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51 (1): 15-36.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61 (5): 759-67.
3. Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 2002; 42: 55-80.
4. Ota S, Bamba H, Kato A, Kawamoto C, Yoshida Y, Fujiwara K. Review article: COX-2, prostanoids and colon cancer. Aliment Pharmacol Ther 2002; 16 Suppl 2: 102-6.
5. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 1999; 59 (20): 5093-6.
6. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001; 276 (21): 18075-81.
7. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99 (3): 335-45.
8. Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci 1998; 39 (3): 581-91.
9. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000; 37 (5): 431-502.
10. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94 (4): 252-66.
11. DuBois RN, Giardiello FM, Smalley WE. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am 1996; 25 (4): 773-91.
12. Kudo T, Narisawa T, Abo S. Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann 1980; 71 (2): 260-4.
13. Pollard M, Luckert PH. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 1980; 64 (12): 1323-7.
14. Pollard M, Luckert PH. Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 1981; 214 (4520): 558-9.
15. Narisawa T, Sato M, Sano M, Takahashi T. Inhibition of development of methylnitrosourea-induced rat colonic tumors by peroral administration of indomethacin. Gann 1982; 73 (3): 377-81.
16. Narisawa T, Satoh M, Sano M, Takahashi T. Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin. Carcinogenesis 1983; 4 (10): 1225-7.
17. Pollard M, Luckert PH, Schmidt MA. The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat. Cancer Lett 1983; 21 (1): 57-61.
18. Narisawa T, Hermanek P, Habs M, Schmahl D. Reduction of carcinogenicity of N-nitrosomethylurea by indomethacin and failure of resuming effect of prostaglandin E2 (PGE2) against indomethacin. J Cancer Res Clin Oncol 1984; 108 (2): 239-42.
19. Metzger U, Meier J, Uhlschmid G, Weihe H. Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis Colon Rectum 1984; 27 (6): 366-9.
20. Pollard M, Luckert PH. Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. J Natl Cancer Inst 1983b; 70 (6): 1103-5.
21. Pollard M, Luckert PH. Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea, Cancer Lett 1984; 25 (2): 117-21.
22. Nigro ND, Bull AW, Boyd ME. Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst 1986; 77 (6): 1309-13.
23. Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987; 47 (20): 5340-6.
24. Ross DS, Bitzer D, Roy T, Murphy JE. Piroxicam inhibits the growth of an adenocarcinoma isograft in Fischer rats. J Surg Res 1988; 45 (3): 249-53.
25. Pollard M, Luckert PH. In vivo model systems for assessing an anti-cancer drug: responses of autochthonous and transplanted prostate tumors to cyclophosphamide. Anticancer Res 1990; 10 (1): 33-6.
26. Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy BS. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 1991; 51 (17): 4528-34.
27. Jacoby RF, Marshall DJ, Newton MA, Novakovic K, Tutsch K, Cole CE, et al. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996; 56 (4): 710-4.
28. Moorghen M, Ince P, Finney KJ, Sunter JP, Appleton DR, Watson AJ. A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J Pathol 1988; 156 (4): 341-7.
29. Moorghen M, Ince P, Finney KJ, Sunter JP, Watson AJ, Appleton DR. The effect of sulindac on colonic tumour formation in dimethylhydrazine-treated mice. Acta Histochem Suppl 1990; 39: 195-9.
30. Skinner SA, Penney AG, O'Brien PE. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch Surg 1991; 126 (9): 1094-6.
31. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993; 14 (8): 1493-7.
32. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24 (1): 83-7.
33. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002; 346 (14): 1054-9.
34. Keller JJ, Offerhaus GJ, Polak M, Goodman SN, Zahurak ML, Hylind LM, et al. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Gut 1999; 45 (6): 822-8.
35. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80 (12): 1618-9.
36. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328 (18): 1313-6.
37. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101 (3): 635-9.
38. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989; 157 (1): 175-9.
39. Rigau J, Piqué JM, Rubio E, Planas R, Tarrech JM, Bordas JM. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991; 115 (12): 952-4.
40. Tonelli F, Valanzano R. Sulindac in familial adenomatous polyposis. Lancet 1993; 342 (8879): 1120.
41. Winde G, Gumbinger HG, Osswald H, Kemper F, Bunte H. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int J Colorectal Dis 1993; 8 (1): 13-7.
42. Hirota C, Iida M, Aoyagi K, Matsumoto T, Tada S, Yao T, et al. Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis. Cancer 1996; 78 (8): 1660-5.
43. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 1994; 74 (7): 1847-54.
44. Peleg II, Lubin MF, Cotsonis GA, Clark WS, Wilcox CM. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci 1996; 41 (7): 1319-26
45. Collet JP, Sharpe C, Belzile E, Boivin JF, Hanley J, Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 1999; 81 (1): 62-8.
46. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48 (15): 4399-404.
47. Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994; 154 (4): 394-9.
48. Reeves MJ, Newcomb PA, Trentham-Dietz A, Storer BE, Remington PL. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 1996; 5 (12): 955-60.
49. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996; 91 (1): 44-8.
50. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999; 159 (2): 161-6.
51. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000; 320 (7250): 1642-6.
52. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83 (5): 355-8.
53. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993; 72 (4): 1171-7.
54. La Vecchia C, Negri E, Franceschi S, Conti E, Montella M, Giacosa A, et al. Aspirin and colorectal cancer. Br J Cancer 1997; 76 (5): 675-7.
55. Freedman AN, Michalek AM, Weiss HA, Zhang ZF, Marshall JR, Mettlin CJ, et al. Aspirin use and p53 expression in colorectal cancer. Cancer Detect Prev 1998; 22 (3): 213-8.
56. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85 (4): 307-11.
57. Coogan PF, Rosenberg L, Louik C, Zauber AG, Stolley PD, Strom BL, et al. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control 2000; 11 (3): 249-55.
58. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121 (4): 241-6
59. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333 (10): 609-14.
60. Kauppi M, Pukkala E, Isomaki H. Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clin Exp Rheumatol 1996; 14 (5): 551-3.
61. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997; 40 (9): 1580-6.
62. Rosenberg L, Louik C, Shapiro S. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 1998; 82 (12): 2326-33.
63. García-Rodríguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 2001; 12 (1): 88-93.
64. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989; 299 (6710): 1247-50.
65. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325 (23): 1593-6.
66. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5 (2): 138-46.
67. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85 (15): 1220-4.
68. Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 1998; 128 (9): 713-20.
69. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998; 339 (18): 1277-84.
70. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Research 1999; 59: 987-990
71. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57 (7): 1276-80.
72. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996; 56 (19): 4424-9.
73. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58: 4997-5001
74. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59: 991-994.
75. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, et al. Genetic Disruption of Ptgs-1, as well as of Ptgs-2, Reduces Intestinal Tumorigenesis in Min Mice. Cancer Res 2000; 60 (17): 4705-4708.
76. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345 (6): 433-42.
77. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18 (55): 7908-16.
78. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000;1470 (2): M69-M78.
79. Δ716 knockout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2). Cell 1996; 87: 803-809.
80. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000; 60 (18): 5040-4.
81. Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61 (4): 1733-40.
82. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107 (4): 1183-8.
83. Maekawa M, Sugano K, Sano H, Miyazaki S, Ushiama M, Fujita S, et al. Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. Jpn J Clin Oncol 1998; 28 (7): 421-6.
84. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995, 55: 2556-2559.
85. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55 (17): 3785-9.
86. Hasegawa K, Ichikawa W, Fujita T, Ohno R, Okusa T, Yoshinaga K, et al. Expression of cyclooxygenase-2 (COX-2) mRNA in human colorectal adenomas. Eur J Cancer 2001; 37 (12): 1469-74.
87. Hao X, Bishop AE, Wallace M, Wang H, Willcocks TC, Maclouf J, et al. Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 1999; 187 (3): 295-301.
88. Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Research 1998; 58: 4823-4826.
89. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999; 282 (13): 1254-7.
90. Ferrandina G, Lauriola L, Distefano MG, Zannoni GF, Gessi M, Legge F, et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 2002; 20 (4): 973-81.
91. Denkert C, Kobel M, Pest S, Koch I, Berger S, Schwabe M, et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002; 160 (3): 893-903
92. Gaffney DK, Holden J, Davis M, Zempolich K, Murphy KJ, Dodson M. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2001; 49 (5): 1213-7.
93. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999; 5 (5): 1001-5.
94. Tomozawa S, Nagawa H, Tsuno N, Hatano K, Osada T, Kitayama J, et al. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer 1999; 81 (8): 1274-9.
95. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, et al, Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000; 6 (10): 4064-8.
96. Chapple KS, Cartwright EJ, Hawcroft G, Tisbury A, Bonifer C, Scott N, et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000; 156 (2): 545-53.
97. Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ, et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA 2002; 99 (3): 1521-1526.
98. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000; 6 (9): 1024-8.
99. Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 1997; 94: 657-662.
100. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999; 18 (2): 305-14.
101. Mann M, Sheng H, Shao J, Williams C, Pisacane P, Sliwkowski M, et al. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001; 120 (7): 1713-1719.
102. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002; 8 (3): 289-93.
103. Jiang D, Yang H, Willson JKV, Liang J, Humphrey LE, Zborowska E, et al. Autocrine Transforming Growth Factor alpha provides a growth advantage to malignant cells by facilitating reentry into the cell cycle from suboptimal growth states. J. Biol. Chem 1998; 273 (47): 31471-31479.
104. Dong J, Opresko LK, Dempsey PJ, Lauffenburger DA, Coffey RJ, Wiley HS. Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. Proc Natl Acad Sci USA 1999; 96 (11): 6235-6240.
105. Black RA. Tumor necrosis factor-alplia converting enzyme. Int J Biochem Cell Biol 2002; 34: 1-5.
106. Carpenter G. EGF receptor transactivation mediated by tile proteolytic production of EGF-like agonists. Sci STKE 2000; 2000 (15): E1.
107. Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 2001; 20 (13): 1594-600.
108. Barnard J, Graves-Deal R, Pittelkow M, DuBois R, Cook P, Ramsey G, et al. Auto- and cross-induction within the mammalian epidermal growth factor- related peptide family. J Biol Chem 1994; 269 (36): 22817-22822.
109. Topham MK, Prescott SM. Mammalian diacylglycerol kinases, a family of lipid kinases with signaling functions. J Biol Chem 1999; 274 (17): 11447-50.
110. Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995; 55 (9): 1811-6.
111. Tsujii M, Dubois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
112. Cao Y, Pearman AT, Zimmerman GA, McIntyre TM, Prescott SM. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA 2000; 97 (21): 11280-5.
113. Lu X, Xie W, Reed D, Bradshaw WS, Simmons DL. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc Natl Acad Sci USA 1995; 92: 7961-7965.
114. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58 (2): 362-6.
115. Elder DJ, Halton DE, Crew TE, Paraskeva C. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int J Cancer 2000; 86 (4): 553-60.
116. Pyo H, Choy H, Amorino GP, Kim JS, Cao Q, Hercules SK, et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001; 7 (10): 2998-3005.
117. Hsueh CT, Chiu CF, Kelsen DP, Schwartz GK. Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis. Cancer Chemother Pharmacol 2000; 45 (5): 389-96.
118. Kamitani H, Geller M, Eling T. Expression of 15-Lipoxygenase by Human Colorectal Carcinoma Caco-2 Cells during Apoptosis and Cell Differentiation. J Biol Chem 1998; 273 (34): 21569-21577.
119. Tang DG, Chen YQ, Honn KV. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci USA 1996; 93 (11): 5241-6.
120. Chen JK, Capdevila J, Harris RC. Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol Cell Biol 2001; 21 (18): 6322-31.
121. Winkler JD, Eris T, Sung CM, Chabot-Fletcher M, Mayer RJ, Surette ME, et al. Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells. J Pharmacol Exp Ther 1996; 279 (2): 956-66.
122. Hayakawa M, Ishida N, Takeuchi K, Shibamoto S, Hori T, Oku N, et al. Arachidonic acid-selective cytosolic phospholipase A2 is crucial in the cytotoxic action of tumor necrosis factor. J Biol Chem 1993; 268: 11290-11295.
123. Cao Y, Dave KB, Doan TP, Prescott SM. Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma. Cancer Res 2001; 61 (23): 8429-34.
124. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998; 95 (2): 681-6.
125. Hong KH, Bonventre JC, O'Leary E, Bonventre JV, Lander ES. Deletion of cytosolic phospholipase A2 suppresses ApcMin-induced tumorigenesis. Proc Natl Acad Sci USA 2001; 98 (7): 3935-3939.
126. Takaku K, Sonoshita M, Sasaki N, Uozumi N, Doi Y, Shimizu T, et al. Suppression of Intestinal Polyposis in ApcDelta 716 Knockout Mice by an Additional Mutation in tile Cytosolic Phospholipase A2 Gene. J. Biol. Chem 2000; 275 (44): 34013-34016.
127. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407 (6801): 242-8.
128. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716.
129. Hoper MM, Voelkel NF, Bates TO, Allard JD, Horan M, Shepherd D, et al. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell Mol Biol 1997; 17 (6): 748-56.
130. Sunayama K, Konno H, Nakamura T, Kashiwabara H, Shoji T, Tsuneyoshi T, et al. The role of cyclooxygenase-2 (COX-2) in two different morphological stages of intestinal polyps in APC (Delta474) knockout mice. Carcinogenesis 2002; 23 (8): 1351-9.
131. Dormond O, Ruegg C. Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives. Drug Resist Updat 2001; 4 (5): 314-21.
132. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285 (5430): 1028-32.
133. Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol 1996; 8 (5): 724-30.
134. Brakebusch C, Bouvard D, Stanchi F, Sakai T, Fassler R. Integrins in invasive growth. J Clin Invest 2002; 109 (8): 999-1006.
135. Montgomery AM, Reisfeld RA, Cheresh DA. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three- dimensional dermal collagen. Proc Natl Acad Sci USA 1994; 91 (19): 8856-60.
136. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin [see comments]. J Clin Invest 1995; 96 (4): 1815-22.
137. Cheresh DA, Stupack DG. Integrin-mediated death: an explanation of the integrin-knockout phenotype? Nat Med 2002; 8 (3): 193-4.
138. Vonlaufen A, Wiedle G, Borisch B, Birrer S, Luder P, Imhof BA. Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. Mod Pathol 2001; 14 (11): 1126-32.
139. Varner JA, Brooks PC, Cheresh DA. The integrin alpha V beta 3: angiogenesis and apoptosis. Cell Adhes Commun 1995; 3 (4): 367-74.
140. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5 (12): 1418-23.
141. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60 (5): 1306-11.
142. Dormond O, Foletti A, Paroz C, Ruegg C. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 2001; 7 (9): 1041-7.
143. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79 (7): 1157-64
144. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002; 8 (1): 27-34.
145. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996; 93 (10): 4816-20.
146. Shao J, Sheng H, Inoue H, Morrow JD, DuBois RN. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 2000; 275 (43): 33951-6.
147. Dixon DA, Tolley ND, King PH, Nabors LB, McIntyre TM, Zimmerman GA, et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 2001; 108 (11): 1657-65.
148. Dimberg J, Samuelsson A, Hugander A, Soderkvist P. Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer. Anticancer Res 1998; 18 (5A): 3283-7.
149. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122 (5): 518-23.
150. Dimberg J, Samuelsson A, Hugander A, Soderkvist P. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 1999; 45 (5): 730-2.
151. Prescott SM, White RL. Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell 1996; 87 (5): 783-6.
152. Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002; 97 (4): 1037-41.
153. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999; 274 (16): 10911-5.
154. Fearon E, Gruber S. Molecular abnormalities in colon and rectal cancer. In: Mendelson J, Howley P, Israel M, Liotta L (eds): The Molecular Basis of Cancer. Philadelphia WB Saunders, 2001: 289-312.
155. Xie W, Herschman HR. v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. J Biol Chem 1995; 270 (46): 27622-8.
156. Xie W, Herschman HR. Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum. J Biol Chem 1996; 271 (49): 31742-8.
157. Subbaramaiah K, Chung WJ, Dannenberg AJ. Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways. J Biol Chem 1998; 273 (49): 32943-9.
158. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002; 277 (21): 18649-57.
159. Howe LR, Crawford HC, Subbaramaiah K, Hassell JA, Dannenberg AJ, Brown AM. PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2. J Biol Chem 2001; 276 (23): 20108-15.
160. Sheng H, Williams CS, Shao J, Liang P, DuBois RN, Beauchamp RD. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem 1998; 273 (34): 22120-7.
161. Sheng H, Shao J, Dubois RN. K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res 2001; 61 (6): 2670-5.
162. Reddy ST, Wadleigh DJ, Herschman HR. Transcriptional regulation of the cyclooxygenase-2 gene in activated mast cells. J Biol Chem 2000; 275 (5): 3107-13.
163. Zhu Y, Saunders MA, Yeh H, Deng WG, Wu KK. Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding proteins. J Biol Chem 2002; 277 (9): 6923-8.
164. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 2001; 480-481: 243-69.
165. Kojima M, Morisaki T, Izuhara K, Uchiyama A, Matsunari Y, Katano M, et al. Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-kappa B activation. Oncogene 2000; 19 (9): 1225-31.
166. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 1998; 115 (2): 297-306.
167. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992 15; 89 (16): 7384-8.
168. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268 (12): 9049-54.
169. Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T. Structure of the human cyclo-oxygenase-2 gene. Biochem J 1994; 302 (Pt 3): 723-7.
170. Conne B, Stutz A, Vassalli JD. The 3′ untranslated region of messenger RNA: A molecular 'hotspot' for pathology? Nat Med 2000; 6 (6): 637-41.
171. Brewer G. Misregulated posttranscriptional checkpoints: inflammation and tumorigenesis. J Exp Med 2001; 193 (2): F1-4.
172. Mendell JT, Dietz HC. When the message goes awry: disease-producing mutations that influence mRNA content and performance. Cell 2001; 107 (4): 411-4.
173. Chen CY, Gherzi R, Ong SE, Chan EL, Raijmakers R, Pruijn GJ, et al. AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell 2001; 107 (4): 451-64.
174. Mukherjee D, Gao M, O'Connor JP, Raijmakers R, Pruijn G, Lutz CS, et al. The mammalian exosome mediates the efficient degradation of mRNAs that contain AU-rich elements. EMBO J 2002; 21 (1-2): 165-74.
175. Wilusz CJ, Wormington M, Peltz SW. The cap-to-tail guide to mRNA turnover. Nat Rev Mol Cell Biol 2001; 2 (4): 237-46.
176. van Hoof A, Parker R. Messenger RNA degradation: beginning at the end. Curr Biol 2002; 12 (8): R285-7.
177. Srivastava SK, Tetsuka T, Daphna-Iken D, Morrison AR. IL-1 beta stabilizes COX II mRNA in renal mesangial cells: role of 3′-untranslated region. Am J Physiol 1994; 267 (3 Pt 2): F504-8.
178. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J Biol Chem 2000; 275 (16): 11750-7.
179. Lasa M, Mahtani KR, Finch A, Brewer G, Saklatvala J, Clark AR. Regulation of Cyclooxygenase 2 mRNA Stability by the Mitogen-Activated Protein Kinase p38 Signaling Cascade. Mol Cell Biol 2000; 20 (12): 4265-4274.
180. Zhang Z, Sheng H, Shao J, Beauchamp RD, DuBois RN. Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells. Neoplasia 2000; 2 (6): 523-30.
181. Brennan CM, Steitz JA. HuR and mRNA stability. Cell Mol Life Sci 2001; 58 (2): 266-77.
182. Fan XC, Steitz JA. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J 1998; 17 (12): 3448-60.
183. Peng SS, Chen CY, Xu N, Shyu AB. RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein. EMBO J. 1998; 17 (12): 3461-70.
184. Keene JD. Why is Hu where? Shuttling of early-response-gene messenger RNA subsets. Proc Natl Acad Sci USA 1999; 96 (1): 5-7.
185. Nabors LB, Gillespie GY, Harkins L, King PH. HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3′ untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res 2001; 61 (5): 2154-61.
186. Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem. 1998; 273 (11): 6417-23.
187. Blaxall BC, Dwyer-Nield LD, Bauer AK, Bohlmeyer TJ, Malkinson AM, Port JD. Differential expression and localization of the mRNA binding proteins, AU-rich element mRNA binding protein (AUF1) and Hu antigen R (HuR), in neoplastic lung tissue. Mol Carcinog 2000; 28 (2): 76-83.
188. Wang W, Fan J, Yang X, Furer-Galban S, Lopez de Silanes I, von Kobbe C, et al. AMP-activated kinase regulates cytoplasmic HuR. Mol Cell Biol 2002; 22 (10): 3425-36.
189. Carballo E, Lai WS, Blackshear PJ. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 1998; 281 (5379): 1001-5.
190. Lai WS, Carballo E, Thorn JM, Kennington EA, Blackshear PJ. Interactions of CCCH zinc finger proteins with mRNA. Binding of tristetraprolin-related zinc finger proteins to Au-rich elements and destabilization of mRNA. J Biol Chem 2000; 275 (23): 17827-37.
191. Carballo E, Lai WS, Blackshear PJ. Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood 2000; 95 (6): 1891-9.
192. Carballo E, Cao H, Lai WS, Kennington EA, Campbell D, Blackshear PJ. Decreased sensitivity of tristetraprolin-deficient cells to p38 inhibitors suggests the involvement of tristetraprolin in the p38 signaling pathway. J Biol Chem 2001; 276 (45): 42580-7.
193. Mahtani KR, Brook M, Dean JL, Sully G, Saklatvala J, Clark AR. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol Cell Biol 2001; 21 (19): 6461-9.
194. Zhang W, Wagner BJ, Ehrenman K, Schaefer AW, DeMaria CT, Crater D, et al. Purification, characterization, and cDNA cloning of an AU-rich element RNA-binding protein, AUF1. Mol Cell Biol 1993; 13 (12): 7652-65.
195. Gueydan C, Droogmans L, Chalon P, Huez G, Caput D, Kruys V. Identification of TIAR as a protein binding to the translational regulatory AU-rich element of tumor necrosis factor alpha mRNA. J Biol Chem 1999; 274 (4): 2322-6.
196. Piecyk M, Wax S, Beck AR, Kedersha N, Gupta M, Maritim B, et al. TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha. EMBO J 2000; 19 (15): 4154-63.
197. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14 (15): 1837-51.
198. Cottrell S, Bicknell D, Kaklamanis L, Bodmer WF. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet 1992; 340 (8820): 626-30.
199. Mei JM, Hord NG, Winterstein DF, Donald SP, Phang JM. Differential expression of prostaglandin endoperoxide H synthase-2 and formation of activated beta-catenin-LEF-1 transcription complex in mouse colonic epithelial cells contrasting in Apc. Carcinogenesis. 1999; 20 (4): 737-40.
200. Dimberg J, Hugander A, Sirsjo A, Soderkvist P. Enhanced expression of cyclooxygenase-2 and nuclear beta-catenin are related to mutations in the APC gene in human colorectal cancer. Anticancer Res 2001; 21 (2A): 911-5.
201. Hsi LC, Angerman-Stewart J, Eling TE. Introduction of full-length APC modulates cyclooxygenase-2 expression in HT-29 human colorectal carcinoma cells at the translational level. Carcinogenesis 1999; 20 (11): 2045-9.
202. Fujita M, Fukui H, Kusaka T, Morita K, Fujii S, Ueda Y, et al. Relationship between cyclooxygenase-2 expression and K-ras gene mutation in colorectal adenomas. J Gastroenterol Hepatol 2000; 15 (11): 1277-81.
203. Flynn A, Proud CG. The role of eIF4 in cell proliferation. Cancer Surv 1996; 27: 293-310.
204. Avery A, Paraskeva C, Hall P, Flanders KC, Sporn M, Moorghen M. TGF-beta expression in the human colon: differential immunostaining along crypt epithelium. Br J Cancer 1993; 68 (1): 137-9.
205. Gilbert RS, Reddy ST, Targan S, Herschman HR. TGF-beta 1 augments expression of the TIS10/prostaglandin synthase-2 gene in intestinal epithelial cells. Cell Mol Biol Res 1994; 40 (7-8): 653-60.
206. Sheng H, Shao J, Hooton EB, Tsujii M, DuBois RN, Beauchamp RD. Cyclooxygenase-2 induction and transforming growth factor beta growth inhibition in rat intestinal epithelial cells. Cell Growth Differ 1997; 8 (4): 463-70.
207. Shao J, Sheng H, Aramandla R, Pereira MA, Lubet RA, Hawk E, et al. Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 1999; 20 (2): 185-91.
208. Sheng H, Shao J, O'Mahony CA, Lamps L, Albo D, Isakson PC et al. Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2. Oncogene 1999; 18 (4): 855-67.
209. Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM, DuBois RN, et al. Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem 2000; 275 (9): 6628-35.
210. Slice LW, Bui L, Mak C, Walsh JH. Differential regulation of COX-2 transcription by Ras- and Rho-family of GTPases. Biochem Biophys Res Commun 2000; 276 (2): 406-10.
211. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem 2000; 275 (20): 14838-45.
212. Zhang F, Subbaramaiah K, Altorki N, Dannenberg AJ. Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem 1998; 273 (4): 2424-8.
213. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5 (7): 810-6.
214. Jang BC, Sanchez T, Schaefers HJ, Trifan OC, Liu CH, Creminon C, et al. Serum withdrawal-induced post-transcriptional stabilization of cyclooxygenase-2 mRNA in MDA-MB-231 mammary carcinoma cells requires the activity of the p38 stress-activated protein kinase. J Biol Chem 2000; 275 (50): 39507-15.
215. Hardwick JC, van den Brink GR, Offerhaus GJ, van Deventer SJ, Peppelenbosch MP. NF-kappaB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps. Oncogene 2001; 20 (7): 819-27.
216. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell 1997; 88 (4): 435-7.
217. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997; 89 (3): 457-67.
218. Sheng H, Shao J, DuBois RN. Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells. J Biol Chem 2001; 276 (17): 14498-504.
219. Marx J. Cancer Research. Antiinflammatories inhibit cancer growth-but how?. Science 2001; 291 (5504): 581-2
220. Piazza GA, Rahm AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995; 55 (14): 3110-6.
221. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996; 52 (2): 237-45.
222. Qiao L, Shiff SJ, Rigas B. Sulindac sulfide inhibits the proliferation of colon cancer cells: diminished expression of the proliferation markers PCNA and Ki-67. Cancer Lett 1997; 115 (2): 229-34.
223. Qiao L, Shiff SJ, Rigas B. Sulindac sulfide alters the expression of cyclin proteins in HT-29 colon adenocarcinoma cells. Int J Cancer 1998; 76 (1): 99-104.
224. Hara A, Yoshimi N, Niwa M, Ino N, Mori H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn J Cancer Res 1997; 88 (6): 600-4.
225. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104 (5): 413-21.
226. Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998; 28 (2): 67-81.
227. Bjarnason I, Hayllar J. Early pathogenic events in NSAID-induced gastrointestinal damage. Ital J Gastroenterol 1996; 28 Suppl 4: 19-22.
228. Moreno-Sánchez R, Bravo C, Vásquez C, Ayala GH, Silveira LH, Martínez-Lavín M. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs; Study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem Pharmacol 1999; 57 (7): 743-752.
229. Ogino M, Hisatomi H, Murata M, Hanazono M. Indomethacin suppresses the growth of colon 26, Meth-A and FM3A tumors in mice by reducing the prostaglandin E2 content and telomerase activity in tumor tissues. Jpn J Cancer Res 1999; 90 (7): 758-64.
230. Murphy VJ, Yang Z, Rorison KA, Baldwin GS. Cyclooxygenase-2-selective antagonists do not inhibit growth of colorectal carcinoma cell lines. Cancer Lett 1998; 122 (1-2): 25-30.
231. Yang Z, Hollande F, Baldwin GS. Blockade of long chain fatty acid oxidation by non-steroidal anti-inflammatory drugs may contribute to inhibition of proliferation of human colorectal carcinoma cell lines. Cancer Lett 1998; 124 (2): 187-91.
232. Baldwin GS, Murphy VJ, Yang Z, Hashimoto T. Binding of nonsteroidal antiinflammatory drugs to the alpha-subunit of the trifunctional protein of long chain fatty acid oxidation. J Pharmacol Exp Ther 1998; 286 (2): 1110-4.
233. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 15 (14): 2742-4.
234. Kishimoto Y, Yashima K, Morisawa T, Shiota G, Kawasaki H, Hasegawa J. Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane. J Gastroenterol 2002; 37 (3): 186-93.
235. Anderson WF, Umar A, Viner JL, Hawk ET. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Design 2002; 8(12): 1035-62.
236. Chauhan DP. Chemotherapeutic potential of curcumin for colorectal cancer. Curr Pharm Design 2002; 8(19): 1695-706.
237. Graham GG, Graham RI, Day RO. Comparative analgesia cardiovascular and renal effects of celecoxib rofecoxib and acetaminophen (paracetamol). Curr Pharm Design 2002; 8(12): 1063-75.